cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc268w7m
title: CCDC 2034320: Experimental Crystal Structure Determination

description: Related Article: De Wang, Zefeng Song, Jianyu Zhang, Tao Xu|2021|Org.Chem.Front.|8|1125|doi:10.1039/D0QO01399D
DOI: 10.5517/ccdc.csd.cc26942r
title: CCDC 2034563: Experimental Crystal Structure Determination

description: Related Article: Xiao-Long Lu, Baochao Yang, Haibing He, Shuanhu Gao|2021|Org.Chem.Front.|8|1143|doi:10.1039/D0QO01346C
DOI: 10.5517/ccdc.csd.cc26bhjl
title: CCDC 2035879: Experimental Crystal Structure Determination

description: Related Article: Shangze Wu, Jonas Žurauskas, Michał Domański, Patrick S. Hitzfeld, Valeria Butera, Daniel J. Scott, Julia Rehbein, Ajeet Kumar, Erling Thyrhaug, Jürgen Hauer, Joshua P. Barham|2021|Org.Chem.Front.|8|1132|doi:10.1039/D0QO01609H
DOI: 10.5517/ccdc.csd.cc26bhkm
title: CCDC 2035880: Experimental Crystal Structure Determination

description: Related Article: Shangze Wu, Jonas Žurauskas, Michał Domański, Patrick S. Hitzfeld, Valeria Butera, Daniel J. Scott, Julia Rehbein, Ajeet Kumar, Erling Thyrhaug, Jürgen Hauer, Joshua P. Barham|2021|Org.Chem.Front.|8|1132|doi:10.1039/D0QO01609H
DOI: 10.5517/ccdc.csd.cc26fddg
title: CCDC 2038665: Experimental Crystal Structure Determination

description: Related Article: Shangze Wu, Jonas Žurauskas, Michał Domański, Patrick S. Hitzfeld, Valeria Butera, Daniel J. Scott, Julia Rehbein, Ajeet Kumar, Erling Thyrhaug, Jürgen Hauer, Joshua P. Barham|2021|Org.Chem.Front.|8|1132|doi:10.1039/D0QO01609H
DOI: 10.5517/ccdc.csd.cc26fyf1
title: CCDC 2039193: Experimental Crystal Structure Determination

description: Related Article: Li-Hua Su, Tian-Ze Li, Chang-An Geng, Yun-Bao Ma, Xiao-Yan Huang, Jin-Ping Wang, Xue-Mei Zhang, Ji-Jun Chen|2021|Org.Chem.Front.|8|1249|doi:10.1039/D0QO01615B
DOI: 10.5517/ccdc.csd.cc26hyf3
title: CCDC 2041115: Experimental Crystal Structure Determination

description: Related Article: Liang Zhang, Neng-Jie Mou, Dong-Rong Xiao, Xin Zhuang, Xiao-Long Lin, Tian Cai, Qun-Li Luo|2021|Org.Chem.Front.|8|1155|doi:10.1039/D0QO01496F
DOI: 10.5517/ccdc.csd.cc26hxtg
title: CCDC 2041096: Experimental Crystal Structure Determination

description: Related Article: Liang Zhang, Neng-Jie Mou, Dong-Rong Xiao, Xin Zhuang, Xiao-Long Lin, Tian Cai, Qun-Li Luo|2021|Org.Chem.Front.|8|1155|doi:10.1039/D0QO01496F
DOI: 10.5517/ccdc.csd.cc26hxvh
title: CCDC 2041097: Experimental Crystal Structure Determination

description: Related Article: Liang Zhang, Neng-Jie Mou, Dong-Rong Xiao, Xin Zhuang, Xiao-Long Lin, Tian Cai, Qun-Li Luo|2021|Org.Chem.Front.|8|1155|doi:10.1039/D0QO01496F
DOI: 10.5517/ccdc.csd.cc26l2rn
title: CCDC 2043171: Experimental Crystal Structure Determination

description: Related Article: Fushuai Li, Shuai Liang, Yepeng Luan, Xuling Chen, Hanhui Zhao, Anqi Huang, Pengfei Li, Wenjun Li|2021|Org.Chem.Front.|8|1243|doi:10.1039/D0QO01505A
DOI: 10.5517/ccdc.csd.cc26lkgv
title: CCDC 2043627: Experimental Crystal Structure Determination

description: Related Article: Hong-Ru Chen, Zhen-Yu Hu, Hua-Li Qin, Haolin Tang|2021|Org.Chem.Front.|8|1185|doi:10.1039/D0QO01430C
DOI: 10.5517/ccdc.csd.cc26n2gf
title: CCDC 2045084: Experimental Crystal Structure Determination

description: Related Article: Zhengshuai Xu, Chaoren Shen, Hongru Zhang, Peng Wang, Kaiwu Dong|2021|Org.Chem.Front.|8|1163|doi:10.1039/D0QO01486A
DOI: 10.5517/ccdc.csd.cc26x8br
title: CCDC 2052954: Experimental Crystal Structure Determination

description: Related Article: Wen-Chao Gao, Jianrong Liu, Xuefeng Jiang|2021|Org.Chem.Front.|8|1275|doi:10.1039/D1QO00001B
DOI: 10.5517/ccdc.csd.cc26x8cs
title: CCDC 2052955: Experimental Crystal Structure Determination

description: Related Article: Wen-Chao Gao, Jianrong Liu, Xuefeng Jiang|2021|Org.Chem.Front.|8|1275|doi:10.1039/D1QO00001B
DOI: 10.5517/ccdc.csd.cc2738vh
title: CCDC 2058736: Experimental Crystal Structure Determination

description: Related Article: Akito Nakai, Tomoki Yoneda, Takayuki Tanaka, Atsuhiro Osuka|2021|Chem.Commun.|57|3034|doi:10.1039/D1CC00518A
DOI: 10.5517/ccdc.csd.cc2738wj
title: CCDC 2058737: Experimental Crystal Structure Determination

description: Related Article: Akito Nakai, Tomoki Yoneda, Takayuki Tanaka, Atsuhiro Osuka|2021|Chem.Commun.|57|3034|doi:10.1039/D1CC00518A
DOI: 10.5517/ccdc.csd.cc2738xk
title: CCDC 2058738: Experimental Crystal Structure Determination

description: Related Article: Akito Nakai, Tomoki Yoneda, Takayuki Tanaka, Atsuhiro Osuka|2021|Chem.Commun.|57|3034|doi:10.1039/D1CC00518A
DOI: 10.5517/ccdc.csd.cc25w1dj
title: CCDC 2021987: Experimental Crystal Structure Determination

description: Related Article: Ying-Ying Zhang, Feng-Yi Qiu, Hua-Tian Shi, Weibin Yu|2021|Chem.Commun.|57|3010|doi:10.1039/D0CC08052G
DOI: 10.5281/zenodo.4627175
title: Dataset related to the article "Novel risk calculator performance in athletes with arrhythmogenic right ventricular cardiomyopathy."

description: This record contains raw data related to the article "Novel risk calculator performance in athletes with arrhythmogenic right ventricular cardiomyopathy." Abstract <strong>Background: </strong>Disease progression and ventricular arrhythmias (VAs) in arrhythmogenic right ventricular cardiomyopathy (ARVC) are correlated with physical exercise, and clinical detraining and avoidance of competitive sport practice are suggested for ARVC patients. An algorithm assessing primary arrhythmic risk in ARVC patients was recently developed by Cadrin-Tourigny et al. Data regarding its transferability to athletes are lacking. <strong>Objective: </strong>The purpose of this study was to assess the reliability of the Cadrin-Tourigny risk prediction algorithm in a cohort of athletes with ARVC and to describe the impact of clinical detraining on disease progression. <strong>Methods: </strong>All athletes undergoing clinical detraining after ARVC diagnosis at our institution were enrolled. Baseline and follow-up clinical characteristics and data on VA events occurring during follow-up were collected. The Cadrin-Tourigny algorithm was used to calculate the a priori predicted VA risk, which was compared with the observed outcomes. <strong>Results: </strong>Twenty-five athletes (age 36.1 ± 14.0 years; 80% male) with definite ARVC who were undergoing clinical detraining were enrolled. Over median (interquartile range) follow-up of 5.3 (3.2-6.6) years, a reduction in premature ventricular complex (PVC) burden (P = .001) was assessed, and 10 VA events (40%) were recorded. The a priori algorithm-predicted risk seemed to fit with the observed cohort arrhythmic risk [mean observed-predicted risk difference over 5 years -0.85% (interquartile range -4.8% to +3.1%); P = .85]. At 1-year follow-up, 11 patients (44%) had an improved stress ECG response, and no significant changes in right ventricular ejection fraction were observed. <strong>Conclusion: </strong>Clinical detraining is associated with PVC burden reduction in athletes with ARVC. The novel risk prediction algorithm does not seem to require any correction for its application to ARVC athletes. <strong>Keywords: </strong>Arrhythmogenic right ventricular cardiomyopathy; Athletes; Clinical detraining; Physical exercise; Risk calculator; Ventricular arrhythmia.
DOI: 10.5281/zenodo.4627174
title: Dataset related to the article "Novel risk calculator performance in athletes with arrhythmogenic right ventricular cardiomyopathy."

description: This record contains raw data related to the article "Novel risk calculator performance in athletes with arrhythmogenic right ventricular cardiomyopathy." Abstract <strong>Background: </strong>Disease progression and ventricular arrhythmias (VAs) in arrhythmogenic right ventricular cardiomyopathy (ARVC) are correlated with physical exercise, and clinical detraining and avoidance of competitive sport practice are suggested for ARVC patients. An algorithm assessing primary arrhythmic risk in ARVC patients was recently developed by Cadrin-Tourigny et al. Data regarding its transferability to athletes are lacking. <strong>Objective: </strong>The purpose of this study was to assess the reliability of the Cadrin-Tourigny risk prediction algorithm in a cohort of athletes with ARVC and to describe the impact of clinical detraining on disease progression. <strong>Methods: </strong>All athletes undergoing clinical detraining after ARVC diagnosis at our institution were enrolled. Baseline and follow-up clinical characteristics and data on VA events occurring during follow-up were collected. The Cadrin-Tourigny algorithm was used to calculate the a priori predicted VA risk, which was compared with the observed outcomes. <strong>Results: </strong>Twenty-five athletes (age 36.1 ± 14.0 years; 80% male) with definite ARVC who were undergoing clinical detraining were enrolled. Over median (interquartile range) follow-up of 5.3 (3.2-6.6) years, a reduction in premature ventricular complex (PVC) burden (P = .001) was assessed, and 10 VA events (40%) were recorded. The a priori algorithm-predicted risk seemed to fit with the observed cohort arrhythmic risk [mean observed-predicted risk difference over 5 years -0.85% (interquartile range -4.8% to +3.1%); P = .85]. At 1-year follow-up, 11 patients (44%) had an improved stress ECG response, and no significant changes in right ventricular ejection fraction were observed. <strong>Conclusion: </strong>Clinical detraining is associated with PVC burden reduction in athletes with ARVC. The novel risk prediction algorithm does not seem to require any correction for its application to ARVC athletes. <strong>Keywords: </strong>Arrhythmogenic right ventricular cardiomyopathy; Athletes; Clinical detraining; Physical exercise; Risk calculator; Ventricular arrhythmia.
DOI: 10.5281/zenodo.4626967
title: Dataset related to the article "STRA-MI-VT (STereotactic RadioAblation by Multimodal Imaging for Ventricular Tachycardia): rationale and design of an Italian experimental prospective study. "

description: This record contains raw data related to the article "STRA-MI-VT (STereotactic RadioAblation by Multimodal Imaging for Ventricular Tachycardia): rationale and design of an Italian experimental prospective study." Abstract <strong>Background: </strong>Ventricular tachycardia (VT) is a life-threatening condition, which usually implies the need of an implantable cardioverter defibrillator in combination with antiarrhythmic drugs and catheter ablation. Stereotactic body radiotherapy (SBRT) represents a common form of therapy in oncology, which has emerged as a well-tolerated and promising alternative option for the treatment of refractory VT in patients with structural heart disease. <strong>Objective: </strong>In the STRA-MI-VT trial, we will investigate as primary endpoints safety and efficacy of SBRT for the treatment of recurrent VT in patients not eligible for catheter ablation. Secondary aim will be to evaluate SBRT effects on global mortality, changes in heart function, and in the quality of life during follow-up. <strong>Methods: </strong>This is a spontaneous, prospective, experimental (phase Ib/II), open-label study (NCT04066517); 15 patients with structural heart disease and intractable VT will be enrolled within a 2-year period. Advanced multimodal cardiac imaging preceding chest CT-simulation will serve to elaborate the treatment plan on different linear accelerators with target and organs-at-risk definition. SBRT will consist in a single radioablation session of 25 Gy. Follow-up will last up to 12 months. <strong>Conclusions: </strong>We test the hypothesis that SBRT reduces the VT burden in a safe and effective way, leading to an improvement in quality of life and survival. If the results will be favorable, radioablation will turn into a potential alternative option for selected patients with an indication to VT ablation, based on the opportunity to treat ventricular arrhythmogenic substrates in a convenient and less-invasive manner. <strong>Keywords: </strong>Cardiac radiosurgery; Catheter ablation; Radioablation; Stereotactic body radiotherapy; Ventricular tachycardia.
DOI: 10.5281/zenodo.4626966
title: Dataset related to the article "STRA-MI-VT (STereotactic RadioAblation by Multimodal Imaging for Ventricular Tachycardia): rationale and design of an Italian experimental prospective study. "

description: This record contains raw data related to the article "STRA-MI-VT (STereotactic RadioAblation by Multimodal Imaging for Ventricular Tachycardia): rationale and design of an Italian experimental prospective study." Abstract <strong>Background: </strong>Ventricular tachycardia (VT) is a life-threatening condition, which usually implies the need of an implantable cardioverter defibrillator in combination with antiarrhythmic drugs and catheter ablation. Stereotactic body radiotherapy (SBRT) represents a common form of therapy in oncology, which has emerged as a well-tolerated and promising alternative option for the treatment of refractory VT in patients with structural heart disease. <strong>Objective: </strong>In the STRA-MI-VT trial, we will investigate as primary endpoints safety and efficacy of SBRT for the treatment of recurrent VT in patients not eligible for catheter ablation. Secondary aim will be to evaluate SBRT effects on global mortality, changes in heart function, and in the quality of life during follow-up. <strong>Methods: </strong>This is a spontaneous, prospective, experimental (phase Ib/II), open-label study (NCT04066517); 15 patients with structural heart disease and intractable VT will be enrolled within a 2-year period. Advanced multimodal cardiac imaging preceding chest CT-simulation will serve to elaborate the treatment plan on different linear accelerators with target and organs-at-risk definition. SBRT will consist in a single radioablation session of 25 Gy. Follow-up will last up to 12 months. <strong>Conclusions: </strong>We test the hypothesis that SBRT reduces the VT burden in a safe and effective way, leading to an improvement in quality of life and survival. If the results will be favorable, radioablation will turn into a potential alternative option for selected patients with an indication to VT ablation, based on the opportunity to treat ventricular arrhythmogenic substrates in a convenient and less-invasive manner. <strong>Keywords: </strong>Cardiac radiosurgery; Catheter ablation; Radioablation; Stereotactic body radiotherapy; Ventricular tachycardia.
DOI: 10.5281/zenodo.4626928
title: Dataset related to the article "Cardiac arrhythmia catheter ablation procedures guided by x-ray imaging: N-acetylcysteine protection against radiation-induced cellular damage (CARAPACE study): study design. "

description: This record contains raw data related to the article "Cardiac arrhythmia catheter ablation procedures guided by x-ray imaging: N-acetylcysteine protection against radiation-induced cellular damage (CARAPACE study): study design." Abstract <strong>Purpose: </strong>Catheter ablation (CA) procedures are characterized by exposure to ionizing radiations (IR). IR can cause DNA damage and may lead to carcinogenesis if not efficiently repaired. The primary endpoint of this study is to investigate whether intravenous administration of N-acetylcysteine prior to CA procedure may prevent systemic oxidative stress and genomic DNA damage induced by exposure to IR. <strong>Methods: </strong>The "Cardiac Arrhythmia catheter ablation procedures guided by x-Ray imaging: N-Acetylcysteine Protection Against radiation induced Cellular damagE" (CARAPACE) study is a prospective, randomized, single-blinded, parallel-arm monocenter study enrolling 550 consecutive patients undergoing CA at the Arrhythmology Unit of Centro Cardiologico Monzino (CCM). Inclusion criteria are age ≥ 18, indication for CA procedure guided by IR imaging, and written informed consent. IR levels will be measured via fluoroscopy time, effective dose, and dose area product. Glutathione and glutathione disulfide concentrations will be measured, and urinary levels of 8-iso-prostaglandin-F<sub>2α</sub> and 8-hydroxy-2-deoxyguanosine will be quantified. The enrolled patients will be randomized 1:1 to the N-acetylcysteine group or to the control group. <strong>Results: </strong>We expect that pre-operative administration of N-acetylcysteine will prevent IR-induced systemic oxidative stress. The study will provide data on oxidative DNA damage assessed by urinary 8-hydroxy-2-deoxyguanosine levels and direct evidence of genomic DNA damage in blood cells by comet assay. <strong>Conclusion: </strong>Catheter ablation procedures can lead to IR exposure and subsequent DNA damage. N-acetylcysteine administration prior to the procedure may prevent them and therefore lead to less possible complications. <strong>Trial registration: </strong>www.clinicaltrials.gov (NCT04154982). <strong>Keywords: </strong>Catheter ablation; DNA damage; Fluoroscopy; Ionizing radiation; Oxidative stress; Radiological risk.
DOI: 10.5281/zenodo.4626927
title: Dataset related to the article "Cardiac arrhythmia catheter ablation procedures guided by x-ray imaging: N-acetylcysteine protection against radiation-induced cellular damage (CARAPACE study): study design. "

description: This record contains raw data related to the article "Cardiac arrhythmia catheter ablation procedures guided by x-ray imaging: N-acetylcysteine protection against radiation-induced cellular damage (CARAPACE study): study design." Abstract <strong>Purpose: </strong>Catheter ablation (CA) procedures are characterized by exposure to ionizing radiations (IR). IR can cause DNA damage and may lead to carcinogenesis if not efficiently repaired. The primary endpoint of this study is to investigate whether intravenous administration of N-acetylcysteine prior to CA procedure may prevent systemic oxidative stress and genomic DNA damage induced by exposure to IR. <strong>Methods: </strong>The "Cardiac Arrhythmia catheter ablation procedures guided by x-Ray imaging: N-Acetylcysteine Protection Against radiation induced Cellular damagE" (CARAPACE) study is a prospective, randomized, single-blinded, parallel-arm monocenter study enrolling 550 consecutive patients undergoing CA at the Arrhythmology Unit of Centro Cardiologico Monzino (CCM). Inclusion criteria are age ≥ 18, indication for CA procedure guided by IR imaging, and written informed consent. IR levels will be measured via fluoroscopy time, effective dose, and dose area product. Glutathione and glutathione disulfide concentrations will be measured, and urinary levels of 8-iso-prostaglandin-F<sub>2α</sub> and 8-hydroxy-2-deoxyguanosine will be quantified. The enrolled patients will be randomized 1:1 to the N-acetylcysteine group or to the control group. <strong>Results: </strong>We expect that pre-operative administration of N-acetylcysteine will prevent IR-induced systemic oxidative stress. The study will provide data on oxidative DNA damage assessed by urinary 8-hydroxy-2-deoxyguanosine levels and direct evidence of genomic DNA damage in blood cells by comet assay. <strong>Conclusion: </strong>Catheter ablation procedures can lead to IR exposure and subsequent DNA damage. N-acetylcysteine administration prior to the procedure may prevent them and therefore lead to less possible complications. <strong>Trial registration: </strong>www.clinicaltrials.gov (NCT04154982). <strong>Keywords: </strong>Catheter ablation; DNA damage; Fluoroscopy; Ionizing radiation; Oxidative stress; Radiological risk.
DOI: 10.5281/zenodo.4626876
title: Dataset related to the article "Differentiating Hereditary Arrhythmogenic Right Ventricular Cardiomyopathy from Cardiac Sarcoidosis Fulfilling 2010 ARVC Task Force Criteria."

description: This record contains raw data related to the article "Differentiating Hereditary Arrhythmogenic Right Ventricular Cardiomyopathy from Cardiac Sarcoidosis Fulfilling 2010 ARVC Task Force Criteria." Abstract <strong>Background: </strong>The clinical presentation of cardiac sarcoidosis (CS) may resemble that of arrhythmogenic right ventricular cardiomyopathy (ARVC). <strong>Objective: </strong>The purpose of this study was to identify clinical variables to better discriminate between patients with genetically determined ARVC and those with CS fulfilling definite 2010 ARVC Task Force Criteria (TFC). <strong>Methods: </strong>In this multicenter study, 10 patients with CS fulfilling definite 2010 ARVC TFC were age and gender matched with 10 genetically proven ARVC patients. A cardiac <sup>18</sup>F-fluorodeoxyglucose positron emission tomographic (<sup>18</sup>F-FDG PET) scan was required for patients to be included in the study. <strong>Results: </strong>The 2010 ARVC TFC did not reliably differentiate between the 2 diseases. CS patients presented with longer PR intervals, advanced atrioventricular block (AVB), and longer QRS duration (P &lt;.001 and P = .009, respectively), whereas T-wave inversions (TWIs) in the peripheral leads were more common in ARVC patients (P = .009). CS patients presented with more extensive left ventricular involvement and lower left ventricular ejection fraction (LVEF), whereas ARVC patients had a larger right ventricular outflow tract (RVOT) (P = .044). PET scan positivity was only present in CS patients (90% vs 0%). <strong>Conclusion: </strong>The 2010 ARVC TFC do not reliably differentiate between CS patients fulfilling 2010 ARVC TFC and those with hereditary ARVC. Prolonged PR interval, advanced AVB, longer QRS duration, right ventricular apical involvement, reduced LVEF, and positive <sup>18</sup>F-FDG PET scan should raise the suspicion of CS, whereas larger RVOT dimensions, subtricuspid involvement and peripheral TWI favor a diagnosis of hereditary ARVC.
DOI: 10.5281/zenodo.4626875
title: Dataset related to the article "Differentiating Hereditary Arrhythmogenic Right Ventricular Cardiomyopathy from Cardiac Sarcoidosis Fulfilling 2010 ARVC Task Force Criteria."

description: This record contains raw data related to the article "Differentiating Hereditary Arrhythmogenic Right Ventricular Cardiomyopathy from Cardiac Sarcoidosis Fulfilling 2010 ARVC Task Force Criteria." Abstract <strong>Background: </strong>The clinical presentation of cardiac sarcoidosis (CS) may resemble that of arrhythmogenic right ventricular cardiomyopathy (ARVC). <strong>Objective: </strong>The purpose of this study was to identify clinical variables to better discriminate between patients with genetically determined ARVC and those with CS fulfilling definite 2010 ARVC Task Force Criteria (TFC). <strong>Methods: </strong>In this multicenter study, 10 patients with CS fulfilling definite 2010 ARVC TFC were age and gender matched with 10 genetically proven ARVC patients. A cardiac <sup>18</sup>F-fluorodeoxyglucose positron emission tomographic (<sup>18</sup>F-FDG PET) scan was required for patients to be included in the study. <strong>Results: </strong>The 2010 ARVC TFC did not reliably differentiate between the 2 diseases. CS patients presented with longer PR intervals, advanced atrioventricular block (AVB), and longer QRS duration (P &lt;.001 and P = .009, respectively), whereas T-wave inversions (TWIs) in the peripheral leads were more common in ARVC patients (P = .009). CS patients presented with more extensive left ventricular involvement and lower left ventricular ejection fraction (LVEF), whereas ARVC patients had a larger right ventricular outflow tract (RVOT) (P = .044). PET scan positivity was only present in CS patients (90% vs 0%). <strong>Conclusion: </strong>The 2010 ARVC TFC do not reliably differentiate between CS patients fulfilling 2010 ARVC TFC and those with hereditary ARVC. Prolonged PR interval, advanced AVB, longer QRS duration, right ventricular apical involvement, reduced LVEF, and positive <sup>18</sup>F-FDG PET scan should raise the suspicion of CS, whereas larger RVOT dimensions, subtricuspid involvement and peripheral TWI favor a diagnosis of hereditary ARVC.